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Summary 
In  previous studies we showed that a chronic colitis associated with a Thl T  cell response can 
be induced by the rectal administration of the haptenizing reagent 2,4,6-trinitrobenzene sul- 
fonic acid  (TNBS). We  report here that  oral administration of haptenized colonic proteins 
(HCP) before rectal administration of TNBS effectively suppresses the ability of  the latter to in- 
duce colitis. This suppression (oral tolerance) appears to be due to the generation ofmucosal T 
cells producing TGF-[3 and Th2-type cytokines after oral HCP administration. Peyer's patch 
and  lamina  propria  CD4+  T  cells  from HCP-fed animals  stimulated  with  anti-CD3/anti- 
CD28 had a 5-10-fold increase in their production of TGF-[3 and secreted increased amounts 
oflL-4 and IL-10 but lower levels oflFN-~ in comparison to T cells from ovalbumin-fed con- 
trol animals.  In addition, the colons of HCP-fed mice showed strikingly increased TGF-[3 but 
decreased IL-12 expression by immunohistochemicat studies  and isolated mononuclear cells 
from HCP-fed animals secreted less IL-12 heterodimer. Finally, and most importantly, the sup- 
pressive effect of orally administered HCP was abrogated by the concomitant systemic adminis- 
tration ofanti-TGF-[3 or rlL-12 suggesting a reciprocal relationship between IL-12 and TGF-[3 
on  tolerance induction  in  TNBS-induced  colitis.  In  parallel  studies  we  demonstrated  that 
TNBS-induced colitis can be transferred to naive recipient animals with purified CD4+ T cells 
from the colon of TNBS-treated animals and that such animals develop lethal pancolitis when 
exposed to very low doses of TNBS. Feeding of HCP suppressed this sensitivity to TNBS, in- 
dicating that oral feeding can suppress  the response of pre-committed T  cells in vivo. These 
studies suggest for the first time that TGF-[3 production can abrogate experimental granuloma- 
tous colitis even after such colitis is established, and thus, that regulation of TGF-[3 levels may 
have relevance to the treatment of human inflammatory bowel disease. 
O 
ral administration of autoantigens and the consequent 
induction of oral tolerance have been shown to sup- 
press experimental autoimmune diseases in animal models, 
such as in experimental autoimmune encephalomyelitis (1, 
2), collagen- (3) and adjuvant-induced arthritis (4), diabetes 
in the non-obese (NOD) 1 mouse (5) and autoimmune uvei- 
tis (6, 7). Recent studies have suggested that the dose of fed 
antigen is an important factor in determining the mecha- 
nism of such "oral tolerance". Whereas high doses of anti- 
gen have been suggested to favor clonal deletion or clonal 
anergy ofThl T  cells, low doses of antigen may induce ac- 
1Abbreviations used in this paper: CD, Crohn's disease; CMFDA, 5-chlo- 
romethylfluorescein  diacetate; DC, dendritic cells; HPC, haptenized co- 
lonic protein; HPF, high power field; IBD, inflammatory  bowel disease; 
LP, Lamina propria; NOD, non-obese; PP, Peyer's  patch; TNBS, 2,4,6- 
trinitrobenzene  sulfonic  acid. 
tive suppression of Thl T  cells resulting in the generation 
of T  cells  that secrete TGF-[3, IL-4,  and IL-10  (2,  8,  9). 
Regardless  of the  mechanism involved, it is possible that 
induction  of oral tolerance can be  used  to  treat autoim- 
mune disease  in humans,  and clinical trials  exploring this 
approach for the  treatment of multiple sclerosis,  rheuma- 
toid arthritis, and uveoretinitis are under way. 
Inflammatory bowel disease  (IBD) encompasses Crohn's 
disease  (CD)  and ulcerative colitis, the major chronic in- 
flammatory diseases  of the gastrointestinal tract in humans 
(10,  11). Recently, various animal models of chronic intes- 
tinal inflammation have been established which will likely 
provide new insights  into the pathogenesis of IBD. These 
include  rats  carrying  transgenes  for  HLA-B27  and  [32- 
microglobulin (12), T  cell reconstituted Tg~26 mice trans- 
genic for the human CD3~ gene (13), and mice in which 
the genes for IL-2 (14), IL-10 (15), Gcq2 (16), and the alpha 
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vated by homologous recombination. In addition,  a  Thl- 
mediated granulomatous colitis model has been established 
by the adoptive transfer of normal CD45R.B hi T  cells from 
BALB/c mice to C.B.-17  scid mice (18).  Importantly, the 
CD45RB l~ CD4+  T  cell population did not cause disease 
and,  if injected  together  with  the  CD45R_B  hi population, 
prevented disease induction (18);  in addition,  this preven- 
tion could be reversed by adding antibodies to TGF-[3, sug- 
gesting a  key negative role  for this  cytokine in disease  in- 
duction. TGF-13 is a pluripotent cytokine that functions as 
potent inhibitor of T  and B  cell proliferation and cytokine 
production  by  macrophages  (19).  The  importance  of this 
inhibitory  function  is  underscored  by  the  finding  that 
TGF-[31  null mice  show  multiorgan inflammation, exces- 
sive lymphocytic infiltrations, and early death (20, 21). 
We  have previously described a  TH1  model of chronic 
intestinal inflammation in mice induced by rectal adminis- 
tration of the hapten reagent 2,4,6-trinitrobenzene sulfonic 
acid (TNBS)(22).  In the present study, we demonstrate that 
TNBS-induced colitis can be adoptively transferred to nor- 
mal mice by in vivo primed lamina propria CD4+  T  cells 
and that TNBS-induced colitis can be suppressed by TGF- 
[3-mediated  oral  tolerance  in mice  fed haptenized  colonic 
proteins even after transfer ofprecommitted  T  cells. These 
results  suggest  that  oral  tolerance  and  the  regulation  of 
TGF-[3 levels may have relevance to  the treatment of hu- 
man inflammatory bowel disease. 
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Figure  1.  TNBS-induced colitis can be adoptively transferred by LP 
CD4+ T cells. (A) Staining for IFN-~/in the colon of a mouse that re- 
ceived CD4+ T cells from TNBS-treated  animals at day 4 after the trans- 
fer. Positive cells were seen in subepithelial areas. ￿  (B) HE-stained 
cross colon section of a mouse that received CD4+ T cells from diseased 
animals and was challenged with low doses of TNBS at day 7 after the 
transfer. There was a loss of goblet cells, colon wall thickening, and severe 
transmural inflammation in the colon.  ￿  100.  (C) IFN-~ secretion by LP 
CD4+ T cells in normal SJL/J mice, TNBS-treated  mice and mice that 
received CD4+ T cells from mice with TNBS-induced colitis or control 
ethanol-treated animals 7 d after the cell transfer. Some mice that received 
the CD4+ T cells were challenged 6 d after the transfer with 0.02 mg TNBS and LP CD4+ cells were isolated the following day. Supernatants of cul- 
tured LP CD4 +  T cells were removed after 2 d and analyzed for IFN-~/concentration  by specific ELISA. A second independent experiment gave similar 
results, (D) HE-stained cross colon section of a mouse that received CD4+ T cells from control ethanol-treated  animals and was challenged with low 
doses of TNBS at day 7 after the transfer. There was neither colon wall thickening nor severe transmural inflammation, X 100. 
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Induction of Colitis.  Specific  pathogen-free  2-4-mo-old female 
SJL/J  mice  were  obtained  from  the  National  Cancer  Institute 
(NCI, Bethesda, MD)  and maintained as described (22).  TNBS- 
colitis was induced as previously described (22). 
Cell Isolation and Purification of Lamina  Propria CD4+  T  Cells. 
Lamina propria (LP)  lymphocytes were isolated from freshly ob- 
tained colonic specimens using the technique of Van der Heijden 
and Stok (23) modified as previously described (22). The resultant 
cells were fu~her enriched by negative selection using mouse CD4 + 
T  cell isolation columns (Isocell; Pierce Co., Rockford,  IL) (22). 
The resultant cells when analyzed by flow cytometry (FACScan| 
Becton Dickinson, Sunnyvale, CA)  contained greater than 85% 
CD4+ T  cells. 
Adoptive Transfer  Of  LP CD4 +  T Cells.  LP cells were isolated ftom 
ethanol-treated mice and mice with TNBS-induced colitis at day 10 
as described above and stained with FITC-labeled rat anti-mouse 
CD4+  antibodies (PharMingen, San Diego,  CA).  CD4+  posi- 
tive cells were then sorted using a FACSTAR Plus  |  (Becton Dick- 
inson) and were >98% pure on reanalysis. CD4+  T  cells (1.5  ￿ 
105) were then injected intravenously into the tail vein of normal 
SJL/J mice. 
Labeling OfCD4+  T Cells.  In some experiments, CD4+ T  cells 
were  labeled before transfer by incubating in 15  IxM 5-chloro- 
methylfluorescein diacetate  (CMFDA)  (Molecular  Probes,  Eu- 
gene, OR,) for 30 min at 37~  and in fresh RPMI for another 30 
rain, followed by two washes in PBS. Finally, cells were intrave- 
nously injected in normal SJL/J mice as described above. 
Immunofluorescence.  To obtain cryosections, tissue samples were 
taken at indicated time points and put into OCT-compound on 
dry ice; sections were cut in a dark room according to standard 
procedures. CMFDA  + cells were visualized on a fluorescence mi- 
croscope at an excitation wavelength of 490 nm. 
Challenge of Mice  That  Received CD4+  T  Cells with  TNBS. 
In some  experiments,  mice  that  received  CD4+  T  cells  were 
challenged 6 d  after transfer by rectal administration of 0.02 mg 
TNBS. 
Grading of Histologic Changes.  Tissues were  removed at  indi- 
cated time points and processed as described (22).  The degree of 
inflammation on microscopic cross sections of the colon was graded 
semiquantitatively from 0 to 5, as previously described (22). 
Generation of Haptenized  Colonic Proteins.  The colons of normal 
SJL/J mice were removed, cut into small strips and mechanically 
homogenized. After filtration straining through a 40-txm nylon cell 
strainer, remaining cells were spun down and removed. Colonic 
protein (1 mg) was then incubated in 0.1% TNBS solution for 4 h 
at room temperature. The resulting solution was dialyzed against 
1￿  PBS overnight at 4~  Haptenization density of proteins was 
determined by  measuring the  photospectrometric  absorption  at 
366 nm using the TNt3S-molarity index (E366  ~  1.1  ￿  104). 
Feeding of Haptenized Colonic Proteins or Control Ovalbumin.  SJL/J 
mice were fed with  100 p,g haptenized colonic protein (HCP), 
TNP-KLH, or control ovalbumin (OVA) in PBS every other day 
over a period of 10 d using a feeding needle. 0.5 mg TNBS was 
then administered intrarectally after an additional 7 d. 
Isolation of Peyer's Patch T Cells.  Peyer's patch (PP)  cells were 
dissected free of the adjacent tissue and put on ice in sterile HBSS 
(Biosource, Rockville, MD)  supplemented with 75 mM Hepes, 
pH  7.2,  penicillin (100 U/ml),  streptomycin (100  txg/ml),  and 
anaphotericin B  (0.5  txg/ml). PP were rinsed twice in 0.05 mM 
DTT in Iscove's modified Dulbecco's media (IMDM)  and sup- 
plemented with 10% heat inactivated FCS, penicillin/streptomy- 
cin, 2-ME (50 p~M; Sigma Chemical), r-glutamine (2 raM), and 
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amphotericin B,  and twice  in supplemented IMDM  alone.  PP 
were then digested with collagenase and DNase I as described above. 
Lymphocyte-enriched populations were isolated from the cells at the 
40--100% interface. Further enrichment was obtained by negative 
selection using mouse T  cell isolation columns as described above. 
The resultant cells, when analyzed by flow cytometry (FACScan| 
Becton Dickinson), contained greater than 85% CD3 +  cells. 
Isolation of Spleen Dendritic Cells.  Spleen  dendritic  cells  (DC) 
were isolated from aseptically removed spleens by digestion with 
collagenase and DNase I as described for PP T cells above; the re- 
suiting  suspension was  plated  on  35-cm  plastic  tissue  culture 
dishes (Falcon Labware, Oxnard, CA) for 60 fifin at 37~  Non- 
adherent cells were washed free with prewarmed PBS, and adher- 
ent cells were cultured for 18 h with supplemented RPMI. DC- 
enriched cells were then washed free with two rinses of warmed 
PBS. As assessed by FACS~-ana/ysis, the resulting cells were  >80% 
N418 positive. To analyze immune responses to HCP,  2  ￿  106 
DC-enriched cells were  incubated with HCP  (1  mg/ml)  over- 
night at 37~  after which the DC were washed twice in RPMI 
and then cultured with 105 LP CD4+  T  cells  in 1 ml complete 
medium. Supernatants were removed at indicated time points and 
analyzed for cytokine concentrations by specific ELISA. 
Cell Culture of T Cells.  Cell cultures of T  cells were performed 
in  complete  medium  consisting of RPMI-1640  supplemented 
with 3 mM r-glutamine, 10 mM Hepes buffer, 10 Ixg/ml genta- 
mycin, 100 U/mi each of penicillin and streptomycin, 0.05 mM 
2ME, and 10% heat-inactivated FCS. For TGF-[3, cell cultures of 
enriched T  cells were performed in serum free medium (GIBCO 
BRL, Gaithersburg, MD) supplemented as above. 
Reagents and Monoclonal Antibodies.  Unconjugated and  bioti- 
nylated monoclonal rat  anti-mouse IL-4  (BVD4-1D11/BVD6- 
24G2), IL-10 (JES5-2A5/SXC-1), and IFN-~/ (R,4-6A2/XMG1.2) 
Table 1.  Histologic  Grading of Colon Sections of HCP- and 
OVA-fed Mice 
Colitis* 
Mild  Severe 
No 
0  1  2  3  4 
Treatment regimen 
Untreated  10  0  0  0  0 
Ethanol  8  2  0  0  0 
TNBS  0  0  3  5  2 
HCP-fed +  TNBS  7  2  1  0  0 
OVA-fed +  TNBS  0  0  4  5  1 
TNP-KLH- fed + 
TNBS  0  2  5  3  0 
Histologic  grading of colon sections from mice that were fed control 
OVA, TNP-KLH or HCP before induction of colitis by TNBS. Colon 
specimens from 10 mice in each group were taken 7 d after administra- 
tion of TNBS and histological grading was performed  as described (22; 
see Materials and Methods).  Data were pooled from three independent 
experiments. 
*See Materials and Methods  for grading criteria. antibodies and recombinant mouse  IL-4  (1  ￿  10  v  units/mg by 
CTLL-2.4 assay), IL-10 (5 X  10  s units/mg), and IFN-y (1  ￿  10  v 
units/mg)  were  purchased  from  PharMingen  and  Genzyme 
Corp. (Cambridge, MA), respectively. For TGF-[3 immunohisto- 
logic staining, purified chicken anti-mouse TGF-[3  (1<&D Sys- 
tems, Minneapolis, MN)  and biotin-labeled rabbit anti-chicken 
IgG  (Zymed,  San  Francisco, CA)  were  used.  Purified hamster 
anti-mouse  CD3~  (clone  145-2C11)  and  hamster  anti-mouse 
CD28  (clone 37.51)  antibodies were obtained from Pharmingen. 
N418 antibodies were kindly provided by Dr. t<. Steinman (24). 
Cytokine  Assays.  To  measure  cytokine production,  24-well 
plates (Costar, Cambridge, MA) were coated with 10 I*g/ml mu- 
rine anti-CD3~ antibody in carbonate buffer (pH 9.6)  overnight 
at 4~  10  s LP CD4+ T  cells were then cultured in 1 ml of com- 
plete medium in precoated or uncoated wells and 1 b~g/ml solu- 
ble anti-CD28 antibody was added to the anti-CD3~-coated wells. 
Cultures were incubated at 37~  in a humidified incubator con- 
taining 6% CO2. After 48  h  (after 60 h  for TGF-[3), culture su- 
pernatants were removed and assayed for cytokine concentration 
(IFN-"/, IL-4, and IL-10) by specific ELISA (PharMingen). TGF-~ 
concentrations were determined using the Predicta TGF-13 ELISA 
Assay (Genzyme Corp.).  Optical densities were  measured on  a 
ELISA reader (MR  5000;  Dynatech Labs.,  ChantiUy, VA)  at  a 
wavelengh of 490 nm. 
Heterodimer-specific  Elispot Assay  for Interleukin-  12.  Macrophage- 
enriched cells from the lamina propria were obtained from lamina 
propria mononudear  cell population using  an  adherence  tech- 
nique  as described for isolation of spleen dendritic cells. In these 
studies however, macrophage adherent cell population were iso- 
lated. 2  ￿  105  macrophage-enriched cells  (70%  F4/80-positive 
cells and 25% N418-positive cells) were incubated for 1.5 d in 96- 
well plates, which had been coated with 5 I~g/ml rat anti-mouse 
IL-12  p75  monoclonal  antibody  (9A5;  Hoffmann-La1<oche, 
Nutley, NJ),  in the presence of 30  p,g/ml Escherichia coli LPS 
(B4:0111;  Sigma  Chemical  Co.,  St.  Louis,  MO).  Next,  plates 
were incubated in blocking buffer (3% BSA/1 ￿  PBS/0.01% Thi- 
omersal) overnight at 4~  washed and 3  btg/rnl biotinylated rat 
anti-mouse IL-12 p40 monoclonal antibody (kindly donated by 
G. Trinchieri) was added and incubation was performed overnight 
at 4~  Streptavidine-alkaline  phosphatase (AP) (1:1,000 dilution; 
a 
24. 
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17 
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Treatment  Regimen 
Untreated  ~  HCP-fed  +TNBS 
Ethanol  ￿9  OVA-fed  + TNBS 
-----e--  TNBS/Ethanol  ----o----  TNP-KLH-fed + TNBS 
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substrate (Western blue stabilized substrate for AP; Promega, Madi- 
son, WI) together with 1% agarose gel was added.  Color reaction 
was allowed to proceed for 36 h. Quantification of spots was per- 
formed in 6  mice per group by examining 25 high power fields 
(HPFs).  Under  our  experimental  conditions  (magnification  of 
400), one HPF represented 0.25 mm  2. 
Proliferation Assays.  Proliferation of cells was assessed by mea- 
suring [3H]TdR incorporation. In brief, 5  ￿  104 T  ceUs/ml were 
cultured in flat-bottomed 96-weU plates (Costar Corp.) for 72 h; 
during the last 8 h  of culture,  1 btCi of [3H]TdR  (New England 
Nuclear, Boston, MA)  (specific activity 6.7 Ci/mmol) was added 
to  each well;  incorporated  [3H]  radioactivity was  measured in a 
scintillation counter (LS2800; Beckman Instruments, Inc., Fuller- 
ton, CA).  Each prohferation assay was done in triplicate. 
Immunohistochemistry.  Cryosections  (7  p,m)  were  air  dried, 
fixed in cold acetone for 3  man at RT,  incubated in 0.6% H20 2 
in methanol for 30 man, rehydrated in PBS plus 0.01% Triton-X 
for 15 man, blocked with 100% normal rabbit serum for 3 h, and 
then incubated with the primary antibody (rat anti-mouse IFN-"/ 
or chicken anti-mouse TGF-~; 1:100 dilution in 10% normal rab- 
bit serum) overnight at 4~  in a dark humid chamber. Sections were 
then washed, incubated with the secondary antibody (biotin-labeled 
rabbit anti-rat IgG  or  rabbit anti-chicken IgG;  1:100  dilution), 
washed in PBS, incubated in peroxidase conjugated streptavidine 
and  chromogen  (3  amino-9-ethylcarbazide;  obtained from  Zy- 
reed) for 15 rain, counterstained with methyl green or hematox- 
yhn,  mounted,  and  analyzed.  Samples  incubated  with  isotype- 
matched control antibodies and without primary antibody served 
as negative controls. 
In Vivo Administration of Anti-TGF-~3 Antibodies or rlL-12.  Ani- 
mals were injected i.p. with 1 mg anti-TGF-J3 antibodies (murine 
IgG1; clone 1.Dl1.16;  Celtrix Corp.,  Santa Clara,  CA) or  1 mg 
control IgG (Jackson ImmunoResearch, West Grove, PA) at in- 
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Figure 2.  TNBS-induced coil- 
tis can be suppressed  by feeding 
of  HCP.  (A)  Weight  changes 
of untreated SJL/J  mice, control 
ethanol-treated mice, and TNBS- 
treated mice treated over a  pe- 
riod of 12 d. Some of the TNBS- 
treated mice were pre-fed HCP, 
TNP-KLH  or OVA for 10 d  as 
specified in Materials and Meth- 
ods; colitis was then induced af- 
ter  an  additional  7  d.  Weight 
data from one representative ex- 
periment ot~t of three is shown. 
Each  point  represents  average 
weight  data  from  four  mice. 
Standard deviations are indicated. 
(/3) Macroscopic  appearence  of 
colons of a  mouse with TNBS- 
induced colitis (top row) and mice 
that were prefed OVA (second  row) 
or HCP  (third row) 7  d  after ad- 
ministration of TNBS.  The bot- 
tom row shows  a control mouse 
that  was  injected  with  ethanol 
alone. There was a severe  colitis 
in TNBS-treated mice that were 
fed OVA but not in those that 
received  HCP.  (C)  HE-stained 
colon section of a HCP-fed SJL/J 
mouse 7 d after administration of 
TNBS. No severe cohtis was ob- 
served.  However,  some  colon 
wall thickening was still present. 
￿  100. (D) HE-stained colon sec- 
tion of a OVA-fed SJL/J  mouse 
7 d after administration  of TNBS. 
Cohtis with loss  of goblet cells 
and  lymphocytic  infiRrations 
was  present.  ￿  (E) Weight 
changes  of SJL/J  mice  that  re- 
ceived 1.5  ￿  105 LP  CD4+  T 
cells at day 0 and then fed HCP 
or OVA at days 0,  2,  4,  and 6, 
followed by administration of 0.5 
mg TNBS at day 10. Each point 
represents  average  weight  data 
from four mice. Standard devia- 
tions are indicated. 
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2610  Oral Tolerance in Experimental Colitis Table 2.  Secretion  of lL-4 and IL-10 in HCP- and 0 VA-fed Mice 
IL-4  IL-10 
Treatment 
regimen  media  otCD3/o~CD28  media  otCD3/otCD28 
ng  / ml  ng /ml 
Untreated  0.5  +  0.1  2.5  +  0.5  0.4 -+ 0.05  0.8  -+ 0.1 
Ethanol  0.4 +  0.1  2.3 -  0.3  0.3  +  0.05  0.7 •  0.05 
TNBS  0.1  +  0.03  0.3  •  0.05  0.5  •  0.04  0.8  +-- 0.08 
HCP-fed +  TNBS  0.9  +  0.1"  6.9  ~- 0.8"  1.2 +-- 0.1"  4.8 •  0.45* 
OVA-fed +  TNBS  0.2 +- 0.06  0.4 --_ 0.05  0.3 •  0.08  0.6 •  0.04 
Secretion oflL-4 and IL-10 by LP CD4 +  T cells in mice that were fed OVA or HCP before administration ofTNBS. LP CD4 +  cells  were iso- 
lated 7 d after administration of TNBS and stimulated with anti-CD3 and anti-CD28. Culture supematants  were removed after 2 d and analyzed  for 
cytokine concentration by specific ELISA. 
*  Significandy  increased  vs. OVA-fed and TNBS control (P ~<0.01). 
dicated  time points.  In some  experiments, mice were  injected 
subcutaneously daily with PBS  or PBS  containing 0.75  tzg re- 
combinant murine IL-12 (2.5 X 108 Roche units/mg; kindly do- 
nated by M. Gately, Hoffmann-LalKoche) at indicated time points. 
Results 
Adoptive  Transfer of TNBS-induced  Colitis by Lamina Pro- 
pria CD4+  T Cells to Normal SJL/J Mice.  We have previ- 
ously described the induction of a  chronic granulomatous 
colitis in normal BALB/c and SJL/J mice by rectal admin- 
istration of the  haptenizing reagent  2,4,6  trinitrobenzene 
sulfonic acid, a colitis dominated by CD4+ T  cells producing 
Thl-type cytokines (22).  To further explore this observa- 
tion, we initially sought to determine whether the develop- 
ment of TNBS-induced lesions could be  adoptively trans- 
ferred to  naive animals with CD4+  T  cells. Accordingly, 
we isolated LP CD4+  T  cells from TNBS-treated (diseased) 
animals or control ethanol-treated animals and injected them 
into normal SJL/J mice. Whereas recipients ofCD4+  T  cells 
from control animals did not develop colitis upon transfer, 
recipients of CD4+  T  cells from diseased animals devel- 
oped mild colitis. Thus, the colons of the latter animals were 
found to contain lymphocytic infiltrates, located mainly in 
the  subepithelial areas,  that  produced  IFN-',/  (Fig.  1  a). 
Moreover,  these  infiltrates  contained  injected  CD4+  T 
cells, since CD4+  T  cells that were labeled in vitro with 
CM-FDA before transfer (see Materials and Methods) were 
demonstrated by fluorescence microscopy in the colons at 
the 7-d post-transfer time point (data not shown). 
To verify the presence of hapten-specific CD4+  T  cells 
in  the  lesions of the  recipient mice,  we  administered to 
some of the mice low doses of TNBS that were shown in 
control experiments not to  cause inflammation in normal 
mice. We found that the challenged mice that had received 
T  cells from mice with TNBS-colitis developed a massive 
pancolitis and  died  within 36  h  (Fig.  1  b).  Furthermore, 
analysis of IFN-~/ secretion by LP  CD4+  T  lymphocytes 
from  these  mice showed very high production of IFN-',/ 
(Fig.  1  c).  In contrast, the  colons of challenged mice that 
had received T  cells from ethanol-treated animals appeared 
histologically normal (Fig.  1  d)  and LP CD4+  T  cells se- 
creted  low  amounts  of IFN-~/  that  were  comparable  to 
those produced by CD4+  T  cells from normal mice (Fig. 1 
c). Taken together, these studies provide strong support for 
the view that TNBS-induced colitis is mediated by IFN-~/- 
producing CD4+  T  cells that are present in colonic tissues. 
Active  Suppression of TNBS-induced  Colitis by  Feeding of 
Haptenized Colonic Proteins.  We next turned our attention 
to  the  question of whether TNBS-induced colitis can be 
suppressed by inducing "oral tolerance" (i.e., unresponsive- 
ness to fed antigen) specific for TNBS-HCP. We generated 
in vitro  HCP  using previously described techniques  (see 
Materials and Methods) and obtained colonic proteins with 
Figure 3.  Cytokine production by LP cells in tolerized and nontolerized animals. (A) Secretion of IFN-'/by LP CD4+ T cells in mice that were fed 
control OVA or HCP before administration  ofTNBS. LP CD4+ T cells were isolated at indicated  time points after administration  of TNBS and stimu- 
lated under various conditions.  Supernatants  of cultured LP CD4+ cells  were removed after 2 d and analyzed  for IFN-~/concentration  by ELISA. (B) Se- 
cretion of TGF-[3 by LP CD4+ T cells in ethanol- or TNBS-treated mice at day 3 and in OVA- and HCP-fed animals 1 and 3 d after administration  of 
TNBS. LP CD4+ T cells  were stimulated  as above, cultured for 2.5 d and culture supematant  was analyzed  for TGF-I3  concentration  by specific ELISA. 
(C) Secretion  of TGF-[3 by PP T cells in OVA- and HCP-fed animals 1 and 3 d after administration  of TNBS. PP T cells were cultured for 2.5 d, and 
culture supernatant  was analyzed  for TGF-[3 concentration  by specific ELISA. (D) Staining  for TGF-[3  in the colon  of an OVA-fed mouse 1 d after ad- 
ministration  of TNBS. Only weak staining  intensity  was observed. X200. (E) Staining  for TGF-[3 in the colon ofa tolerized HCP-fed mouse 1 d after 
administration  of TNBS. There was a high staining  intensity in subepithelial  areas. X250. (F) Staining  analysis  in the colon ofa tolerized HCP-fed mouse 
1 d after administration  of TNBS using an IgG control antibody. X  250. 
2611  Neurath et al. Table 3.  Proliferation  Assays of PP T Cells in HCP- and 
0 VA-fed Mice 
[3H]Thymidine Incorp. 
Treatment 
regimen  Media  aCD3/ccCD28 
cpm 
Ethanol  13030 +  359  89085 +  876 
TNBS  26663  +  561  154874 +  12923 
OVA-fed + 
TNBS ld  21977 +  765  134021 +  13211 
OVA-fed + 
TNBS 3d  24121 _  982  161965 -4- 18717 
HCP-fed + 
TNBS ld  8974 -+ 743*  24198  •  1877" 
HCP-fed + 
TNBS 3d  11865 +  855*  39478 +  4876* 
Proliferation assays of PP T cells in OVA- or HCP-fed animals were 
performed 1 and 3 d after administration ofTNBS. PP T cells (1 ￿  105) 
were cultured for 2 d and [3H]thymidine was added during the last 8 h 
of the culture as described in Materials and Methods. Data were pooled 
from three experiments. Standard deviations are indicated. 
*  Significantly reduced compared with corresponding OVA-fed control 
(p ~o.ol). 
very high haptenization densities of 53-74 TNP groups per 
105  Da  of protein.  Mice  were  then  fed  HCP  or control 
protein  (ovalbumin  [OVA]) for 10  d;  then,  after an addi- 
tional  7  d,  TNBS  was administered per rectum.  Whereas 
sham-fed animals administered TNBS developed severe coli- 
tis, diarrhea, and weight loss (Fig. 2 a), mice fed HCP failed 
to  develop diarrhea  and weight loss,  and their colons ap- 
peared macroscopically intact (Fig. 2 b). Furthermore, these 
mice showed no histologic signs  of severe colitis (Fig.  2 c). 
In contrast, mice fed OVA showed clear macroscopic (Fig. 
2 b) and histologic (Fig.  2 d) evidence of colitis that was in- 
distinguishable  from  that  in  normal  mice  given  TNBS. 
Furthermore, TNP-KLH-fed mice showed less weight loss 
than  OVA-fed mice but still  exhibited  colonic  inflamma- 
tion, as assessed by histologic analysis  (Table  1), suggesting 
that the tolerance observed after feeding of HCP might be 
at least partially due to the TNP itself. 
Since these results  showed that TNBS-induced colitis  can 
be prevented by feeding of HCP, we next analyzed whether 
HCP would also be protective when disease was transferred 
by LP CD4+  T  cells from mice with TNBS-induced coli- 
tis.  In these experiments, we isolated colonic LP CD4+  T 
cells from mice with TNBS-induced colitis at day 10,  and 
transfered these  cells  to  normal mice.  The  recipient mice 
were fed four times with HCP and then, after an additional 
4 d 0.5 mg TNBS was administered per rectum. As shown 
in Fig.  2 e, oral feeding of HCP suppressed colitis induced 
by the transfer of in vivo primed CD4+  T  cells. These re- 
sults suggest that the inflammation secondary to stimulation 
of preexisting TNBS-specific CD4+  T  cells is inhibited by 
the induction oral tolerance. 
LP CD4+  T Cells and PP T Cells in HCP-fed Tolerized Mice 
Display Reduced Proliferative Capacity and Secrete High Amounts 
ofTGF-fl, IL-4, andlL-lO.  To  determine  the  mechanisms 
underlying the  tolerance induced  by feeding of HCP, we 
next focused on the capacity of intestinal LP cells in HCP- 
and  OVA-fed  mice  to  produce  various  cytokines.  Since 
previous studies  had  shown  that  TNBS-induced  colitis  is 
critically dependent on IL-12 levels (22), we first analyzed the 
ability ofmacrophage-enriched LP cells from HCP-fed tol- 
erized  mice  to  secrete  functionally  active  IL-12  hetero- 
dimer. We found that cells from the LP of HCP-fed mice 
secreted strikingly less IL-12 heterodimer than those from 
the lamina propria of OVA-fed mice (4.2  +  0.8 vs. 69  + 
12 spot forming cells per HPF). Furthermore, as assessed by 
immunohistochemistry,  there  was  a  marked  reduction  in 
IL-12 heterodimer expression by macrophages in the colon 
of HCP-fed  mice  compared  with  those  from  OVA-fed 
mice  (data  not  shown)  suggesting  that  IL-12-dependent 
Thl cell development was suppressed in .HCP-fed mice. 
This hypothesis was supported by the analysis  of IFN-y 
production  in  tolerized mice 7  d  after TNBS  administra- 
tion. In these studies, we stimulated LP CD4+ T  cells with 
anti-CD3/anti-CD28  and  measured  the  concentration  of 
IFN-y in  culture  supematants.  As  shown  in  Fig.  3  a,  LP 
CD4+  T  cells  from  TNBS-treated  mice  that  were  fed 
OVA  produced  large  amounts  of IFN-'y at  day  7  (com- 
pared  with  mice  not  treated  with  TNBS),  while  T  cells 
from mice fed HCP produced strikingly lower amounts of 
IFN-% In contrast, as shown in Table 2, secretion of IL-4 
and IL-10 was significantly higher in HCP-fed mice than 
in OVA-fed mice (P ~<0.01). 
In additional studies, we measured TGF-]3 production by 
LP CD4+  and PP T  cells in OVA- and HCP-fed mice. In 
this case,  we stimulated both LP CD4+  T  cells and PP T 
cells either with anti-CD3/anti-CD28 or with isolated den- 
dritic cells loaded with HCP. As shown in Fig.  3, b  and c, 
TGF-[3 production by both cell populations and both meth- 
ods of stimulation was strongly increased in cells from mice 
fed HCP compared with cells from mice fed OVA. Addi- 
tional studies showed that FACS|  anti-CD3/anti- 
CD28-stimulated CD4+ T  cells from the lamina propria of 
HCP-fed  mice  produced  higher  levels  of TGF-f3  than 
those from OVA-fed mice (1.2  ng/ml vs.  0.1  ng/ml).  To 
obtain direct evidence of TGF-[3 production  in vivo, we 
performed immunohistochemical staining for this cytokine. 
As shown in  Fig.  3,  d-f,  there was an increase in staining 
intensity for TGF-[3 by LP cells in HCP-fed animals com- 
pared  with  OVA-fed  control  animals  after  TNBS  chal- 
lenge.  Finally, we measured the proliferation of PP T  cells 
from HCP and OVA-fed mice. We found that PP T  cells 
from mice fed HCP when stimulated with anti-CD3  and 
anti-CD28,  proliferated  significantly  less  than  cells  from 
mice fed OVA (P ~<0.01) suggesting that the proliferation 
of these cells  was actively suppressed by increased TGF-~ 
secretion (Table 3). 
2612  Oral Tolerance in Experimental Colitis a 
24. 
;[3. 
22. 
A 
2O 
19- 
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17 
I 
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Treatment  regimen 
10 
r~  TNSS/E 
~-  HCP-fed  + TNBS 
HCP-fed  +  TNBS 
=--  0.01  mg anti-TGFl~ 
o  0.10 mg anti-TGF[~ 
r  1.00 mg anti-TGFl~ 
r~  0.01  mg ratlgG 
A  0.10 mg rat IgG 
￿9  .  1.00 mg ratlgG 
gate  tolerance  and  allow  development  of TNBS-induced 
lesions. To explore this possibility, we treated mice in vivo 
with anti-TGF-[3 or contol IgG on days 0, 4, 7, and 11  af- 
ter feeding HCP. As shown in Fig. 4  a,  anti-TGF-[3 treat- 
ment abrogated the protective effects of  feeding of HCP on 
TNBS-induced  colitis  in  a  dose-dependent  manner.  The 
anti-TGF-[3-treated  mice  displayed  clinical  and  histologic 
signs of colitis (Fig. 4 b) similar to those observed in TNBS- 
treated mice. In addition, cytokine profiles ofLP CD4+  T 
cells in HCP-fed, anti-TGF-[3-treated mice were similar to 
those  of mice  given TNBS  intrarectally  in  the  absence  of 
feeding  HCP  (Table  4).  These  studies,  together  with  the 
TGF-[3  production  studies  described  above,  strongly sug- 
gest that TGF-[3  mediates  the  protective  effect of feeding 
of HCP in TNBS-induced colitis. 
Suppression  of  TNBS-induced  Colitis by  Feeding of Hap- 
tenized  Colonic Proteins Can  Be Abrogated by  High  Doses of 
rlL-12.  In  further  studies,  we  tested  whether  increased 
levels  of IL-12  could  counteract  the  suppressive  effect  of 
oral antigen administration.  To test this hypothesis, we sys- 
temically  administered  IL-12 to  mice  that  were  fed HCP 
and  then  examined  the  effects  of such  treatment  on  the 
clinical  course  of the  TNBS-induced  disease.  As  depicted 
in  Fig.  5, when high  doses  of IL-12 were  administered,  a 
striking  reduction  of the  suppression  of TNBS-induced 
colitis  by feeding  of HCP was  seen.  In contrast,  systemic 
administration  of antibodies  to  IL-12 augmented  the  sup- 
pressive  effects  seen  after  feeding  of  HCP  in  TNBS- 
induced colitis (data not shown). These results establish the 
reciprocal functional relationship  between IL-12 and TGF-[3 
on tolerance induction in TNBS-induced colitis. 
Systemic Administration of TGF-fl Prevents TNBS-induced Coli- 
tis.  Since the above data implied the importance of  TGF-[3 
levels  on the  clinical  course  of TNBS-induced  cohtis,  we 
wanted  to  determine  in  a final series  of studies  if systemic 
administration  of TGF-[3  would  be  sufficient  to  prevent 
TNBS-induced colitis. Accordingly, we treated mice every 
other day with  recombinant  TGF-[3,  starting  one  day be- 
fore  administration  of TNBS  over  a  period  of 11  d.  As 
shown in Fig.  6, high  doses  of TGF-~  abrogated diarrhea 
and  weight  loss  in  TNBS-treated  animals,  suggesting that 
high  levels  of TGF-[3  are  sufficient  to  prevent  TNBS- 
induced colitis. 
Figure 4.  In vivo administration of antibodies to TGF-[3 abrogates the 
suppressive effects of feeding HCP.  (A) Weight changes of SJL/J mice 
that received 0.01-1 mg of anti-TGF-[3 antibodies at days 0, 4, 7, and 11 
after oral feeding with HCP.  Mice receiving rat lgG served as control. 
Weight data from one representative experiment out of two is shown. 
Each point represents average weight data from five mice. Standard devi- 
ations are indicated. (/3) HE-stained colon section of a HCP-fed SJL/J 
mouse that was treated with 1 mg TGF-13-antibodies as described above 
9 d after admimstration of TNBS. Severe colitis was present. ￿  150. 
Administration of Anti-TGF-[3 In Vivo Abrogates the Protec- 
tive Effects of Orally Administered HCP.  If,  indeed,  increased 
TGF-[3 production was responsible for the oral tolerance to 
HCP, pretreatment of mice with anti-TGF-[3 should abro- 
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Discussion 
In the present study we explore the cellular mechanisms 
that regulate experimental TNBS-induced cohtis. First, we 
show in adoptive transfer studies that TNBS-induced coli- 
tis can be mediated by CD4+  T  cells  that home to colonic 
tissue.  Second, we demonstrate that TNBS-induced colitis 
can be actively suppressed via oral tolerance by feeding of 
HCP  and  that  such  tolerance  is  critically  dependent  on 
TGF-[3 production by intestinal cells.  Third and finally, we 
show that  colitis  due  to  transferred  CD4+  T  cells  can be 
suppressed by feeding of HCP, indicating that the oral tol- 
erance  mechanism  affects  precommitted  T  cells  and  thus Table 4.  Production  of Cytokines in Anti-TGF-fl-treated SJL/l Mice 
IFN-'y  IL-4  IL-10 
Group  Media  CD3/28  Media  CD3/28  Media  CD3/28 
Ethanol (E)  4  12  0.4  2.0  0.4  0.8 
E  +  1 mg oeTGF-[3  10  25  0.2  0.8  0.2  0.5 
TNBS  55  534  0.1  0.3  0.4  0.7 
HCP-fed +  TNBS 
No ctTGF-[3  3  27  1.0  4.9  1.5  5.1 
0.1 mg otTGF-[3  14  76  0.8  2.0  1.2  3.1 
1.0 mg otTGF-[3  63  421  0.2  0.5  0.3  0.6 
0.1  mg rat IgG  4  20  0.8  4.6  1.2  4.4 
1.0 mg rat IgG  3  27  1.0  4.9  1.6  4.9 
HCP-fed or unfed mice were treated with ethanol or TNBS and some mice received injections with antibodies  to TGF-[3 at days 0, 4, 7, and 11. LP 
CD4+ cells were isolated 9 d after administration  of TNBS or ethanol.  Culture supernatants  were removed after 2 d and analyzed for cytokine con- 
centration by specific ELISA. A slight increase in IFN-'y production was found in ethanol-treated mice that were given anti-TGF-[3 compared with 
ethanol-treated mice. A second independent experiment gave similar results. 
may  be  relevant  to  the  treatment  of inflammatory  bowel 
disease in humans. 
Inflammatory bowel diseases comprising Crohn's  disease 
(CD)  and ulcerative colitis are thought  to be immunologi- 
cally mediated diseases of the gastrointestinal tract (11).  Re- 
g 
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TNBS  ----~--  HCP-fed  + TNBS + PBS 
*  HCP-fed + TNBS  ￿9  HCP-fed  + TNBS + rlL-12 
Figure 5.  Administration  of rlL-12 abrogates the suppressive effects of 
feeding HCP. Weight changes ofHCP-fed SJL/J mice that were systemi- 
cally treated with riLl2 (days -1, 1, 3, 5, 7, and 9) after administration of 
TNBS.  Weight data  from one experiment out of two is shown.  Each 
point represents average weight data from four mice. Standard deviations 
are indicated. 
cently,  several murine  models  of chronic  intestinal  inflam- 
mation have been described that mimic some characteristics 
of CD  in  humans  including transfer  of CD45RB hi  T  cells 
from Balb/c mice into  scid mice  (18)  and  hapten  reagent- 
induced colitis by TNBS (22). Both models show some histo- 
logic  similarity  (transmural  inflammation,  granuloma  for- 
mation,  infiltration of CD4+  T  cells, and macrophages)  to 
23 
22 
21 
3  2o 
18 
17 
16 
J 
10  0 
days 
Treatment Regimen 
-'--Q----  TNBS  ￿9  TNBS +  100 ng TGF-~ 
#  TNBS +  10 ng TGF-p  ~  TNBS +  I000 n9 TGF-~ 
Figure 6.  Systemic administration  of rTGF-13 prevents TNBS-induced 
colitis. Weight changes of SJL/J mice that were treated with rTGF-13 at 
days -1, 1, 3, 5, 7, 9, and 11 after administration  of TNBS. Weight data 
from one representative experiment  out of two is shown. Each point rep- 
resents average weight data from five mice.  Standard deviations are indi- 
cated. 
2614  Oral Tolerance in Experimental Colitis CD in humans and CD4+  T  cells in both diseases reveal a 
Thl  cytokine pattern that is consistent with the cytokine 
pattern found in CD (Fuss,  I., M. Neurath, M. Boirivant, 
J.  Klein,  C.  de la Motta,  S.  Strong,  C.  Fioccihi, and W. 
Strober,  manuscript  in  preparation).  In  the  CD45RB  hi 
transfer model, it was shown that treatment of mice with 
antibodies  to  IFN-y  ameliorates  disease,  whereas  in  the 
TNBS model, it was shown that anti-IL-12 (which down- 
regulates  IFN-'y production)  abrogates  disease  even  after 
the disease is well established. 
Further insight into the regulation of experimental colitis 
was gained in the present studies of TNBS-induced colitis 
in which the effect of  induction of oral tolerance to TNBS- 
haptenated colonic proteins on TNBS-induced colitis was 
determined. In particular,  we showed that prefeeding of HCP 
to mice not only prevented TNBS-induced colitis at the 
clinical  and  histologic level but  also  prevented the  Thl- 
type T  cell response that accompanies and presumably me- 
diates this colitis. In addition, regarding the mechamsm of 
the oral tolerance, we showed that tolerization to HCP was 
accompanied  by  elevated  production  of Th2-type  cyto- 
kines and strikingly increased TGF-[3 secretion in mucosal 
tissues  (in PP and LP) in vivo. Finally, we found that oral 
tolerance was abrogated in mice administered anti-TGF-[3 
and  that  systemic  adminstration  of  TGF-[3  prevented 
TNBS-induced disease.  These results  indicate clearly that 
TGF-[3 is  a  necessary condition  for the  establishment  of 
oral tolerance to TNBS-haptenated colonic proteins. 
In  further studies,  we  showed that T  cell-enriched LP 
and PP cells from tolerized animals produce high amounts 
of TGF-~ upon in vitro stimulation and displayed reduced 
proliferative capacities. The observation that fed HCP pre- 
vented TNBS-induced colitis  via induction  of cells  pro- 
ducing TGF-[3 supports and extends the work of Miller et 
al.  (25)  who demonstrated the presence of bystander sup- 
pression  mediated  by  TGF-[3  after  feeding  of antigen. 
Weiner  (9,  25-27)  has  recently proposed  that  mucosally 
derived TGF-[3-producing CD4+  T  cells are a special  T 
helper subset  that is induced upon low-dose oral antigen 
administration,  provides  mucosal  T  helper  function  and 
downregulates Thl  T  cell function. After their induction, 
such cells may migrate to other tissues including the lamina 
propria, where they exert TGF-[3-mediated suppressive ef- 
fects on CD4+  T  cells and macrophages that might other- 
wise cause inflammation. This suppressor mechanism could 
explain  the  protective effect of feeding of TNBS-hapte- 
nated proteins on TNBS-induced colitis.  In particular, since 
TGF-[3 has been shown to be a potent inhibitor of IL-12- 
induced Thl development (28), TGF-[3-producing cells gen- 
erated  upon  feeding may prevent  IL-12-dependent  Thl 
cell development upon which TNBS-induced colitis is criti- 
cally dependent (22). Furthermore, oral tolerance induction 
led to a striking reduction of IL-12 heterodimer secretion 
by LP cells that might further account for the suppression 
of Thl  cytokine production. Finally, taken together with 
the fact that administration  of exogenous IL-12 abrogates 
tolerance induction,  the  results suggest a reciprocal func- 
tional relationship between IL-12 and TGF-13 on tolerance 
induction in TNBS-induced colitis. 
The concept of induction of oral tolerance mediated by 
TGF-[3 has important implications to the treatment of au- 
toimmune diseases generally: for instance, it has been shown 
that  one  can suppress  PLP peptide-induced experimental 
autoimmune  encephalitis  by  feeding  MBP  or  antigen- 
induced arthritis by feeding collagen type II. These findings 
have led to the design of a rational immunotherapy for pa- 
tients with rheumatoid arthritis  (29)  and multiple sclerosis 
(30)  and promising clinical trials  are currently in progress. 
The present data,  in  showing that  TNBS-induced colitis 
can be actively suppressed by feeding HCP via induction of 
TGF-[3 secretion in the mucosal tissues and that oral toler- 
ance can also abrogate experimental colitis when disease was 
transferred by LP CD4+  T  cells, suggest that induction of 
oral tolerance has therapeutic relevance to immunologic dis- 
eases of the gastrointestinal tract, such as Crohn's disease. 
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